Patients are increasingly seeking information from their doctor about what treatment will cost them, but providers are unprepared for such conversations.

The state no longer wants to deal with secret price negotiations with individual hospitals for its 727,000-member state employee health plan.

The lobbying groups aren't happy about President Donald Trump's plan to borrow from Europe's system of paying for some high-cost drugs.

A new advocacy group is outspokenly defending high drug prices and criticizing advocates for lower drug prices. Who are they?